Compare Abeona Therapeutics Inc (ABEO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Standard Lithium Ltd — how do they compare? Abeona Therapeutics Inc trades at $7.33 (market cap $421.19M), while Standard Lithium Ltd trades at $2.42 (market cap $604.50M). The key difference: Standard Lithium Ltd is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | SLI | |
|---|---|---|
Market Cap | $421.19M | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $7.45 | $5.65 |
52-Week Low | $4.17 | $1.93 |
Enterprise Value | $276.10M | $467.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
SLI trades at $2.43, down 3.95% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported negative profitability metrics, including a -16.6% ROE and -$48.40M net income for 2025, but has beaten EPS estimates in two recent quarters. Recent news highlights institutional buying and progress on its South West Arkansas lithium project, supported by a $225M DOE grant.
The outlook hinges on successful project execution and lithium production timeline, with analyst consensus strongly bullish (100% buy ratings). Key risks include persistent negative cash flow from operations and high capital expenditure needs, which could pressure the balance sheet if project delays occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
